Frontiers in Pain Research (Nov 2023)

Investigating the effectiveness of oral ketamine on pain, mood and quality of life in treatment resistant chronic pain

  • Sammy Al Mukhaizeem,
  • Sammy Al Mukhaizeem,
  • Anurag Nasa,
  • Anurag Nasa,
  • Dympna Waldron,
  • Dympna Waldron,
  • Alex McDaid,
  • Alex McDaid,
  • Patrick J. Gorman,
  • Patrick J. Gorman,
  • Molly Featherstone,
  • Molly Featherstone,
  • Megan Barry,
  • Megan Barry,
  • Paul Murphy,
  • Paul Murphy,
  • Paul Murphy,
  • Hugh Gallagher,
  • Shrijit Nair,
  • Michael O’Connor,
  • Linda Kelly,
  • Emma O'Hora,
  • Roisin Dolan,
  • Siaghal Mac Colgain,
  • Jack McGrath,
  • Stephane Blouin,
  • Elena Roman,
  • Elena Roman,
  • Laura Gaffney,
  • Darren William Roddy,
  • Darren William Roddy,
  • Kirk John Levins,
  • Kirk John Levins,
  • Kirk John Levins

DOI
https://doi.org/10.3389/fpain.2023.1268985
Journal volume & issue
Vol. 4

Abstract

Read online

IntroductionChronic pain is defined as pain lasting longer than 3 months. This often causes persistent emotional distress and functional disability that is refractory to conventional treatments. Emerging evidence suggests that oral Ketamine therapy may have a specific role in managing treatment-resistant chronic pain. This study aimed to assess the effectiveness of oral ketamine within a tertiary chronic pain management clinic.MethodsThis study was a clinic-based retrospective descriptive study of 79 patients with a broad range of chronic pain diagnoses and treated with oral ketamine over a period up to 12 years. Changes in pain, mood and quality of life (QoL) were assessed using a numerical pain severity score, the Brief Pain Inventory (BPI), the Public Health Questionnaire (PHQ-9) and American Chronic Pain Association Quality of Life (QoL) scale.Results73 patients were accessible for follow-up (mean daily dose and treatment duration were 193.84 mg and 22.6 months respectively). Pain scores decreased (p < 0.0001) on both numerical scores (41.6% decrease) and BPI scoring (mean decrease 2.61). Mood improved (p < 0.0001) across both PHQ-9 and BPI measurements. Patients also reported less difficulty with daily activities and improved QoL. The most common adverse reaction was drowsiness (21.9%), with 30.1% reporting no adverse reactions from Ketamine.DiscussionThis work adds to the growing body of evidence that under the supervision of a pain specialist, oral ketamine therapy may be a safe, tolerable and effective treatment for chronic pain conditions which have not responded to other management options. Further research is required to produce a more accurate understanding of its chronic use. Key messageThis real-world study shows that patients being treated with oral ketamine for chronic pain report decreased severity of pain, improved mood and increased quality of life across all conditions.

Keywords